# A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission

> **NCT00808509** · PHASE4 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 33 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **BIOLOGICAL:** adalimumab
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT00808509
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2013-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00808509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00808509, "A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00808509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*